RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures

Osteoporosis Clinical Trial

Official title:

Randomized Controlled Study of a Local Osteo-Enhancement Procedure (LOEP) to Prevent Secondary Hip Fractures in Osteoporotic Women Undergoing Treatment of Index Hip Fractures

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04796350
• Other study ID #: AGN-CIP-100 / AGN-CIP-100-CA
• Status: Recruiting
• Phase: N/A
• Start date: April 24, 2021
• Est. completion date: April 1, 2029

Study information

• Verified date: March 2024
• Source: AgNovos Healthcare, LLC
• Contact: Adam Lowe
• Phone: +1-240-676-2200
• Email: restore[@]agnovos.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A randomized controlled trial to evaluate AGN1 to prevent secondary hip fractures in osteoporotic women undergoing treatment of index hip fractures. Up to 2400 subjects will be randomized between a treatment group and a control group. Subjects will be followed for a minimum of 5 years after undergoing hip fracture repair surgery.

Description:

This is an event driven, randomized, controlled, prospective, single blinded (non-blinded in Canada), multi-national study.

This study is designed to demonstrate that the AGN1 LOEP treatment can reduce the incidence of secondary hip fractures in subjects presenting with an index hip fracture and undergoing hip fracture repair surgery. Subjects presenting with an index fragility hip fracture who will undergo hip fracture repair will be enrolled. Subjects will be randomized 1:1 into the following two study groups:

1. Treated Group - receives standard of care to repair the index hip fracture and AGN1 LOEP treatment on the target unfractured contralateral hip

2. Control Group - receives standard of care to repair the index hip fracture and no AGN1 LOEP treatment on the target unfractured contralateral hip

AGN1 LOEP is an elective procedure that will be performed immediately following hip fracture repair.

Subjects will be followed through scheduled visits conducted at 6 weeks, 6 months, and every 6 months thereafter for a minimum of 5 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2400
• Est. completion date: April 1, 2029
• Est. primary completion date: April 1, 2027
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

1. Subject is a postmenopausal female at least 1-year post menses and at least 65 years of age.

2. Subject presents with a low-energy index fragility hip fracture in one hip and will undergo surgical repair of the fractured hip.

3. Subject has at least one of the following additional risk factors for a secondary hip fracture (as determined by subject or legally authorized representative (LAR) interview or medical record review):

• Documented falls assessment indicating subject is at moderate or high risk of falls

• Falls history (2 or more falls in the previous 12 months)

• History of vertigo, dizziness, or postural hypotension

• Documented T-score < -2.5 at the hip

• Taking more than 3 daily prescription medications

• Visual impairment as confirmed by one of the following:

• Subject reports difficulty seeing

• Lack of depth perception or vision loss in one eye

• Macular degeneration

• Cataracts

• Prior non-hip fragility fracture

• Cognitive frailty as assessed by SPMSQ (mild or moderate cognitive impairment) or delirium

• Parkinson's disease stage 3 or 4

• 10-year hip fracture probability >15% using the FRAX® Fracture Risk Assessment Tool of the clinical site country

4. Subject is expected to be ambulatory after the hip fracture repair procedure.

5. Informed consent is provided by the subject or the subject's LAR.

6. The subject's willingness, ability, and commitment to participate in screening, treatment, and all follow-up evaluations for the full duration of the study has been documented.

Exclusion Criteria:

1. Subject hospital admission is > 24 hours from the time of the index hip fracture.

2. Subject was dependent on the use of a wheelchair or was bedridden prior to the index hip fracture.

3. Subject is currently enrolled in another clinical study.

4. Subject has a history of hip surgery or previous hip fracture on the target unfractured hip contralateral to the index hip fracture.

5. Subject has one or more new fractures in addition to the index hip fracture at admission that, in the opinion of the investigator, would further compromise patient mobility, rehabilitation, and/or recovery or subject has three or more new fractures in addition to the index hip fracture.

6. Subject has an infection at the LOEP intended treatment site or has non-intact skin or acute traumatic injuries with open wounds close to the area of intended LOEP treatment.

7. Subject has a progressive increase in undiagnosed pain in the target hip contralateral to the index fractured hip over the previous 3 months that in the opinion of the Investigator may suggest underlying bone or joint pathology on the unfractured side.

8. Subject has radiological evidence of gross bony or joint pathology of the hip, including signs predictive of atypical femoral fractures (e.g. cortical beaking), or has been diagnosed and/or treated for atypical femoral fractures.

9. Subject is at ASA Class IV, V, or VI.

10. Subject has a history of metabolic bone disease other than osteoporosis (e.g., Paget's disease, renal osteodystrophy, or osteomalacia).

11. Subject has a history of Pott's disease.

12. Subject has a history of any invasive malignancy (except nonmelanoma skin cancer), unless treated with curative intent and with no clinical signs or symptoms of the malignancy for 5 years.

13. Subject has chronic cardiac insufficiency or severe cardiovascular disease as assessed by a subject or LAR interview to be NYHA Class III or IV or has an implanted pacemaker.

14. Subject has a history of cardiovascular events (e.g. stroke, transient ischemic attack, myocardial infarction, unstable angina, pulmonary embolus, deep vein thrombosis, ventricular tachycardia, or atrial fibrillation) in the last 3 months.

15. Subject is on oral or parenteral immuno-suppressive drugs.

16. Subject has uncontrolled diabetes mellitus.

17. Subject has Hb = 9 g/dL at admission.

18. Subject has severe renal insufficiency defined as an estimated glomerular filtration rate (eGFR) = 30 mL/min.

19. Subject has a diagnosed and ongoing calcium metabolism disorder.

20. Subject has a Parker Mobility Score = 5.

21. Subject has severe cognitive impairment as assessed by SPMSQ.

22. Subject has known allergies to calcium-based bone void fillers.

23. In the judgement of the Investigator, the subject is not a good study candidate (e.g., inability to maintain follow-up schedule, comorbidity or poor general physical/mental health, or drug or alcohol abuse issues).

24. Subject fails pre-operative or intraoperative eligibility criteria as specified in section 7.4.2. of the clinical investigation plan.

Related Conditions & MeSH terms

• Fractures, Bone
• Fragility Fracture
• Hip Fractures
• Osteoporosis

Intervention

Device:
• AGN1 LOEP treatment
the implantation site is injected with the AGN1 implant material

Locations

Country	Name	City	State
Austria	Innsbruck Hospital	Innsbruck
Denmark	Aarhus University Hospital	Aarhus
France	CHU Grenoble-Alpes	Grenoble
France	CHU Lyon	Lyon
France	CHU Toulouse	Toulouse
Germany	University Hospital of Duesseldorf	Düsseldorf
Germany	Justus Liebig Universitat Gießen	Gießen
Germany	Medizinische Hochschule Hannover	Hannover
Germany	Universitatsklinikum Schleswig-Holstein	Kiel
Germany	Klinikum der Universität München	München
Germany	University Hospital of Münster	Münster
Germany	Universitätsklinikum Regensburg	Regensburg
Germany	BG Klinik Tuebingen	Tuebingen
Italy	Azienda Ospedaliero Universitaria Careggi	Firenze
Italy	ASST Gaetano Pini CTO	Milano
Italy	University Hospital San Raffaele Milano	Milano
Italy	Policlinico Tor Vergata	Rome
Japan	Akita City Hospital	Akita-shi	Akita
Japan	The University of Tokyo Hospital	Bunkyo-Ku	Tokyo
Japan	St. Mary's Hospital	Fukuoka
Japan	Iwata City Hospital	Iwata
Japan	Jutendo University Shizuoka Hospital	Izunokuni City	Shizuoka
Japan	Kanto Rosai Hospital	Kawasaki City	Kanagawa
Japan	Shin-yurigaoka General Hospital	Kawasaki-Shi	Kanagawa
Japan	Shin-Yurigaoka General Hospital	Kawasaki-shi
Japan	Southern Tohoku General Hospital	Koriyama	Fukushima
Japan	Chikamori Hospital	Kouchi City	Kochi
Japan	National Hospital Organization Kumamoto Medical Center	Kumamoto
Japan	Kagawa Rosai Hospital	Marugame	Kagawa
Japan	Hyogo Prefectural Nishinomiya Hospital	Nishinomiya	Hyogo
Japan	Okayama Medical Center	Okayama City	Okayama
Japan	Saga-Ken Medical Centre Koseikan	Saga
Japan	Japanese Red Cross Shizuoka Hospital	Shizuoka
Netherlands	Deventer Hospital	Deventer
Netherlands	Saint Anna Ziekenhuis	Geldrop
Netherlands	Maastricht UMC	Maastricht
Netherlands	Isala Hospital	Zwolle
Spain	Clinic de Barcelona	Barcelona
Spain	Vall d'Hebron University Hospital	Barcelona
Spain	Hospital Universitario de Basurto	Bilbao
Spain	Galdakao-Usansolo Hospital	Galdakao
Spain	Hospital Neuro-Traumatológico de Jaén	Jaén
Spain	Hospital Clínico San Carlos	Madrid
Spain	Hospital Universitario 12 de Octubre	Madrid
Spain	PARC Tauli	Sabadell
Spain	Mutua de Terrassa University Hospital	Terrassa
Spain	Valladolid University Clinic Hospital	Valladolid
United Kingdom	Birmingham Heartlands Hospital	Birmingham	England
United Kingdom	Royal Infirmary of Edinburgh	Edinburgh	Scotland
United Kingdom	Leicester Royal Infirmary	Leicester	England
United Kingdom	Nottingham University Hospitals, Queen's Medical Center	Nottingham

Sponsors (5)

Lead Sponsor	Collaborator
AgNovos Healthcare, LLC	Avania, BioClinica, Inc., CMIC Co, Ltd. Japan, Emergent Clinical Consulting, LLC

Countries where clinical trial is conducted

Austria,  Denmark,  France,  Germany,  Italy,  Japan,  Netherlands,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cumulative incidence of secondary fragility hip fractures	Comparison of incidence of secondary fragility hip fractures in the target hip among the Treated Group vs. Control Group.	Interim Analysis, approximately 30 Months
Primary	Cumulative Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)	Comparison of incidence of AEs and SAEs among the Treated Group vs. Control Group.	Interim Analysis, approximately 30 Months
Secondary	Areal bone mineral density (aBMD)	Total hip areal bone mineral density in target hips of the Treated Group compared to the Control Group	12 months and 24 months
Secondary	Trabecular Bone Score (TBS)	Continuous densitometry measure of the target hip bone of the Treated Group compared to the Control Group	12 months and 24 months

External Links

•   Japan Registry of Clinical Trials